There is increasing evidence that improving patient outcomes and cultivating value in the healthcare environment will require health economics and outcomes research (HEOR). Nicole Hengst, research director, Health Strategies Group, provided a unique perspective into some of the ways that payers can utilize HEOR to guide their decision-making practices.
There is increasing evidence that improving patient outcomes and cultivating value in the healthcare environment will require health economics and outcomes research (HEOR). Nicole Hengst, research director, Health Strategies Group, provided a unique perspective into some of the ways that payers can utilize HEOR to guide their decision-making practices.
Ms Hengst says her organization, Health Strategies Group, which provides market insight research to pharmaceutical and biotechnology professionals, conducted a survey of 71 payer executives from health plans, employers, and pharmacy benefit managers. It also included a more intense 30 minute interview process with 25 of those respondents. The survey probed into how these payers view HEOR studies, how they use HEOR studies to make access decisions in the top therapeutic categories, and how their decision-making or patient engagement processes are evolving due to the use of HEOR studies.
The Health Strategies Group found that payers perceive greater value in studies from particular HEOR sources. Academic or third party vendors were cited as “highly reliable.” They also found that payers utilize information from biopharmaceutical companies for contracting decisions. Payers rely on internal HEOR data to make decisions, including those for formulary decisions or treatment plans. The data was found to influence access restrictions and interventions.
“As we go from a fee-for-service to value-based [model], we put strain on our hospitals, health systems, and providers. So what are they looking to do? They need information, analytics, tools, data capture, [etc.] to make the right decisions and HEOR becomes that tool,” said Ms Hengst.
She suggested that the Montefiore Medical Center in Bronx, New York was just one health system that has successfully integrated HEOR into their strategic planning. Organizations like Montefiore can examine HEOR data and decide where to invest resources for treating conditions such as asthma, cancer, hepatitis, and HIV.
HEOR is only expected to increase in the next 2 to 5 years, said Ms Hengst. She explained it is due to:
HEOR provides stakeholders with a variety of other opportunities. Aside from making informed decisions about medical or pharmacy benefit design, it will allow payers to focus on a disease state. It will also help them to align with other stakeholders—including the “3-prong” payer, provider and patient arrangement—and to collaborate with others seeking to innovate.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More